| Objective To detect the levels of serum Sestrin2, ubiquitin specific protease (USP) 13, and soluble triggering receptor expressed on myeloid cells 2 (sTREM) 2 in patients with acute pancreatitis (AP), and to explore the association between serum Sestrin2, USP13, sTREM2 and the disease severity and organ failure. Methods From April 2022 to December 2024, 250 AP patients admitted to Jingmen People’s Hospital were designated as the pancreatitis group. Complying with the severity of the condition, they were grouped into the mild group (88 cases), moderate to severe group (95 cases), and severe group (67 cases), and further divided into the non-failure group (193 cases) and failure group (57 cases) based on the presence of organ failure. Another 250 healthy individuals who underwent physical examination were recruited as the control group. Enzyme-linked immunosorbent assay (ELISA) was performed to measure serum Sestrin2, USP13, and sTREM2. Spearman method was performed to explore the correlation between serum Sestrin2, USP13, sTREM2 and the severity of AP. Logistic regression was performed to explore the influencing factors of organ failure in AP patients. Receiver operating characteristic (ROC) curve was used to analyze the forecasting value of serum Sestrin2, USP13, and sTREM2 for organ failure. Results The pancreatitis group had higher serum Sestrin2 and sTREM2, and lower USP13 than the control group (P<0.05). The Sestrin2 and sTREM2 in the mild, moderate to severe, and severe groups showed an increasing trend, while USP13 showed a decreasing trend (P<0.05). Serum Sestrin2 and sTREM2 were positively correlated with the severity of AP (r=0.454, 0.498, both P<0.001), while USP13 was negatively correlated with the severity of AP (r=-0.415, P<0.001). The failure group had higher BISAP, Sestrin2, and sTREM2 than the non-failure group, and lower USP13 than the non failure group (P<0.05). Elevated BISAP, Sestrin2, sTREM2, and decreased USP13 were risk factors for organ failure in AP patients (P<0.05). The value of joint of serum Sestrin2, USP13, and sTREM2 in forecasting organ failure in AP patients was higher than individual forecasts (P<0.05). Conclusion The serum Sestrin2 and sTREM2 in AP patients increase, while USP13 decreases. The trend of changes in serum indicators is correlated with the disease severity. Serum Sestrin2, USP13, and sTREM2 are expected to become forecasting factors for the occurrence of organ failure, and the forecasting value of joint applications is relatively high. |
